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Abstract 
This study investigated and compared the absorption, metabolism, and subsequently, the 
tissue distribution and excretion of hydroxytyrosol (HT) administered either in its free 
form or through its naturally occurring esterified precursors, namely oleuropein (OLE) 
and its aglycone forms known as secoiridoids (SEC). Here, rats were fed a diet 
supplemented with the equivalent of 5 mg phenol/kg/day for 21 days and the HT 
metabolites in the gastrointestinal digesta (stomach, small intestine and caecum), 
plasma, urine and metabolic tissues (liver and kidney) were analysed. Compared to HT 
and SEC, OLE showed greater stability during digestion, and, consequently, the 
bioavailability based on the urine excretion of HT metabolites was higher. OLE, as a 
glycoside molecule, reached the colon unaltered generating more diverse microbial 
metabolites. In terms of bioavailability, findings suggest that OLE might be the most 
suitable precursor of HT for incorporation into foods or nutraceutical formulations.  
Keywords: Hydroxytyrosol; Microbial catabolism; Metabolic pathways; Olive oil, 
Phenolic compounds 
1. INTRODUCTION
In recent years, numerous epidemiological and dietary intervention studies have 
demonstrated that plant-food consump-tion, attributed to bioactive chemical 
compounds, is directly associated with a lower risk of suffering chronic disease (Sikand, 
Kris-Etherton, & Boulos, 2015). The growing interest in these phyto-chemicals has 
enhanced the development and marketing of food supplements and nutraceuticals, 
which have become the fastest growing segments of the food industry. Over the last 
 
decade, different engineering technologies (such as high pressure, supercritical fluid and 
molecular distillation) have been applied to extract components from raw materials or 
waste products and optimize their form and chemical structure to make them suitable 
for inclusion in new food products (Herrero, del Pilar Sánchez-Camargo, Cifuentes, & 
Ibáñez, 2015). 
Specifically, an important expansion of the nutraceutical market has been observed with 
olive products due to the health benefits associated with their polyphenols (de Bock et 
al., 2013). The evidence of the protective effect of virgin olive oil (VOO) polyphenols 
for cardiovascular diseases (CVD) has been strengthened by the approved health claim 
based on the scientific report of the Panel on Dietetic Products, Nutrition and Allergies 
of EFSA (European Food Safety Authority) (COMMISSION REGULATION (EU) N° 
432/2012 of 16 May 2012): 
Olive oil polyphenols contribute to the protection of blood lipids from oxidative 
stress. The claim may be used only for olive oil which contains at least 5 mg of 
hydroxytyrosol and its derivatives (e.g. oleuropein complex and tyrosol) per 20 g of 
olive oil. 
 
The most abundant polyphenols in olive fruit are oleuropein (OLE), demethyl-
oleuropein, ligstroside and nüzhenide (El Riachy, Priego-Capote, León, Rallo, & Luque 
de Castro, 2011). During mechanical extraction of VOO, hydrolysis reactions take place 
due to the activity of endogenous β-glucosidases, and aglycone derivatives known as 
secoiridoids (SEC) are released. From a chemical standpoint, SEC are characterized by 
the presence of elenolic acid (EA) or some of its derivatives, and hydroxytyrosol (HT) 
or tyrosol (TYR) in their molecule. The most abundant SEC in VOO are the dialdehydic 
form of decarboxymethyl EA linked to HT termed 3,4-DHPEA-EDA and the isomer of 
oleuropein aglycone (3,4-DHPEA-EA). 
Based on the potential benefits of HT and its derivatives, different extracts or 
ingredients are available on the market. These are mainly obtained from the olive leaf, 
olive oil by-products (pomace) or waste-water, and the chemical nature of the phenolic 
compounds varies with the source. Generally, the extracts obtained from olive leaves 
are rich in OLE, the pomace yield extracts are rich in SEC and the waste-water gives 
extracts rich in HT. In this context, phenolic extracts derived from olive products can 
provide HT in different chemical structures, which could influence its uptake and 
metabolism. In the case of flavanols, it has been shown that their stereochemical 
configuration has a profound influence on their uptake and metabolism and their 
bioefficacy (Ottaviani et al., 2011). Similarly, the biological activity of the equol, a 
metabolite produced in vivo from the soy phytoestrogen daidzein by the action of gut 
microflora, depends on the enantiomers R-equol and S-equol (Muthyala et al., 2004). 
Considering the wide range of phenolic extracts derived from olive products available 
on the market, this study was designed to study differences in the absorption and 
metabolism of HT either in its free form or through its natural occurring esterified 
precursors: oleuropein (OLE) and its aglycone forms known as secoiridoids (SEC). For 
 
this proposal, rats were fed a diet supplemented with the equivalent of 5 mg phenol/kg 
rat weight for 21 days. The metabolism in the gastro-intestinal tract (GIT) was studied 
through the determination of the phenolic compounds and their metabolites in the 
contents (digesta) of the stomach, small intestine and caecal and in the faeces. Plasma, 
24 h-urine and the metabolic tissues of liver and kidney were also analysed. 
 
2. MATERIALS AND METHODS 
 
2.1. Chemicals and reagents 
Hydroxytyrosol (HT) was provided by Seprox Biotech (Madrid, Spain), oleuropein by 
Extrasynthese (Genay, France), and homovanillic acid by Fluka Co. (Buchs, 
Switzerland). Catechol, p-hydroxyphenyl-acetic acid, 3,4-dihydroxyphenyl-acetic acid, 
3-(4-hydroxyphenyl)propionic acid and hippuric acid were from Sigma-Aldrich (St. 
Louis, MO, USA). Ortophosphoric acid (85%) was purchased from Panreac (Barcelona, 
Spain). Hydroxytyrosol-3′-O-glucuronide (97.8% of purity), hydroxyl-tyrosol-4′-O-
glucuronide (96.4% of purity), and homovanillic alcohol-4′-O-glucuronide (99.3% of 
purity) were synthe-sized according to the method reported by (Khymenets et al., 2006). 
Hydroxytyrosol-3-O-sulphate was purchased from Toronto Research Chemicals Inc. 
(Toronto, ON, Canada). Methanol and acetonitrile (HPLC-grade) were purchased from 
Scharlab (Barcelona, Spain). Milli-Q water was obtained from a Milli-Q water 
purification system (Millipore Corp., Medford, MA, USA). 
 
2.2. Secoiridoid extract (SEC) 
 
Secoiridoid extract was obtained from olive pomace by Pressurized Liquid Extraction 
(PLE), using an accelerated solvent extractor (ASE 100 Dionex, Sunnyvale, CA, USA) 
based on our previously described method (Suárez, Romero, Ramo, Macià, & Motilva, 
2009). Briefly, 10 g of freeze-dried olive-cake were mixed with 5 g of diatomaceous 
earth. The best extraction of phenolic compounds was obtained with these conditions: 
ethanol/water (80:20, v/v) solvent at 80 °C, 60% setting volume and two static cycles of 
5 min in each extraction. Finally, the sample was purged with nitrogen (≥99.99% purity, 
Alphagaz, Madrid, Spain). After that, the ethanol  
was rotary evaporated until its elimination (Buchi Rotavapor, New Castle, DE, USA). 
Aqueous extract was freeze-dried and stored at −80 °C in N2 atmosphere until use. 
The extract was mainly composed of 3,4-DHPEA-EDA (85%) and contained minor 
proportions of free HT and other secoiridoids providing HT such as 3,4-DHPEA-EA 
(Table S1 Supplementary Material). To calculate the administered dose of 5 mg/kg 
weight of SEC, only 3,4-DHPEA-EDA was considered as it is the main secoiridoid 
derivative providing HT. 
2.3. Animals and experimental procedure 
 
Thirty-two male and female Wistar rats weighing between 300 and 350 g were obtained 
 
from Charles River Laboratories (Barcelona, Spain). They were separated into four 
groups of 8 rats in each group (4 males, 4 females). Group A: Control, group B: 
hydroxytyrosol (HT), group C: secoiridoids (SEC) and group D: oleuropein (OLE) (Fig. 
1). During the 21-day experiment, the animals were housed two per cage at a 
temperature- (21 ± 1 °C) and humidity controlled (55 ± 10%) room with a 12-h light/ 
dark cycle. Food and water were available ad libitum. The animal procedures were 
conducted in accordance with the guidelines of the European Communities Directive 
86/609/EEC regulating animal research and approved by the Animal Ethics Committee 
of Universitat de Lleida (CEEA 10-06/14, 31st July 2014). 
For the supplemented diets, commercial feed pellets (Harlan Laboratories, Madison, 
WI, USA) were crushed in an industrial mill and mixed with Milli-Q 
 
Fig. 1 – Experimental design of the study. µSPE, microelution solid-phase extraction; 
UPLC-MS/MS, Ultra-Performance liquid chromatography coupled to tandem MS.  
 
water containing the equivalent of 5 mg of OLE, SEC or HT/kg rat weight in 16 g of 
crushed pellet (average daily consumption of each rat), respectively. New pellets were 
prepared and freeze-dried. Food and animals were weighed every 2 days to adjust the 
weekly dose of phenolic compound to 5 mg/kg rat weight/day. On the first day before 
treatment (day 0) and after treatment (day 21), the rats were caged in metabolic gavage 
for 24 hours to collect urine and faeces. The rats were sacrificed by intracardiac 
puncture after isoflurane anaesthesia (IsoFlo, Veterinarian Esteve, Bologna, Italy). 
Blood was collected in EDTA tubes and plasma samples were obtained by 
centrifugation (3000 × g, 10 min at 4 °C) and stored at −80 °C until analysis. After 
blood collection, the rats were perfused with an isotonic solution of sodium chloride 
(NaCl) 0.9% to remove the remaining blood irrigating the tissues and their livers and 
kidneys were excised. Additionally, the digestive tract was excised and the contents of 
stomach, small intestine and caecum were obtained to analyse the phenolic metabolites, 
 
expressed as nmols/g digesta. The small intestine content consisted of a pool of 
duodenum, jejunum and ileum contents. All samples were stored at −80 °C and freeze-
dried for phenolic extraction and chromatographic analysis (Fig. 1). 
 
2.4. Sample pre-treatment for phenolic metabolites analysis 
 
Plasma and urine samples were processed using OASIS hydrophilic–lipophilic balance 
(HLB) µElution plates 30 µm (Waters, Milford, MA, USA). Pre-treatment of plasma 
was performed according to our method developed previously (Suárez et al., 2009). 
Briefly, 350 µL of plasma were mixed with 300 µL of phosphoric acid (4%) and 50 µL 
of catechol as the internal standard (IS). Then, the mixture was centrifuged and the 
supernatant was treated by microelution solid-phase extraction (µSPE). The cartridges 
were conditioned sequentially by using 250 µL of methanol and acidified Milli-Q water 
(Milli-Q water at pH 2 with diluted hydrochloric acid). After loading the plasma 
mixture, the plates were washed with 200 µL of Milli-Q water and 200 µL of 5% 
methanol. The retained phenolic compounds were then eluted with 2 × 50 µL of 
methanol and directly injected into the UPLC-MS/MS system. For the analysis of the 
urine samples, the cartridges were conditioned as described previously (Serra et al., 
2013). Briefly, 100 µL of urine were mixed with 50 µL of phosphoric acid (4%) and 50 
µL of catechol as IS, and this solution was loaded into the µSPE. The retained phenolic 
compounds were then eluted with 2 × 50 µL of methanol and injected into the UPLC-
MS/MS system.  
For the analysis of the GIT contents (stomach, small intestine and caecum) and faeces, 
100 mg of freeze-dried sample was suspended in 1 mL of methanol/water (1:1, v/v). 
Each sample was shaken in a vortex (Multi vortex, VWR, Franklin, MA, USA) for 10 
min. After that, the sample was centrifuged at 8784 × g for 10 min and supernatant was 
collected and centrifuged under the same conditions. Finally, the supernatant was 
filtered with 0.22 µm syringe filter and transferred into chromatographic vials until the 
chromatographic analysis.  
The kidney and liver samples were sequentially pretreated with a combination of 
liquid–solid extraction (LSE) combined with µSPE (Serra et al., 2012). Briefly, for the 
analysis of LSE, 60 mg of freeze-dried sample was mixed with 50 µL of ascorbic acid 
(1%), 100 µL of phosphoric acid (4%), and 50 µL of catechol. The samples were treated 
four times with 400 mL of water/methanol/phosphoric acid 4% (94:4.5:1.5, v/v/ v). In 
each extraction, the sample was sonicated for 30 s maintaining the sample in ice to 
avoid heating and then centrifuged. The supernatants were collected, and an aliquot of 
350 µL was treated with µSPE following the same method described above for the 
plasma samples. 
 
2.5. Chromatographic analysis 
The phenolic compounds were analysed by Acquity Ultra-Performance™ liquid 
chromatography coupled to tandem MS as the detector system (UPLC-MS/MS) from 
 
Waters (Milford, MA, USA), as reported in our previous study (Serra et al., 2012). The 
column was an Acquity UPLC™ HSS T3 from Waters (100 mm, 2.1 mm i.d., 1.8 µm 
particle size). The mobile phase was 0.2% (v/v) acetic acid as solvent A and methanol 
as solvent B, with a flow rate of 0.4 mL/min. The gradient was performed as follows: 0–
6 min, 3–15% B; 6–14 min, 15–70% B; 14–17 min, 70–00% B; 17–18 min, 100–3% B; 
18–20 min, 3% B isocratic. The injection volume was 2.5 µL. The UPLC system was 
coupled to a PDA detector, AcQuity UPLC™ and a triple quadrupole detector (TQD™) 
mass spectrometer (Waters). The software used was MassLynx 4.1. Ionization was done 
by electrospray (ESI) in the negative mode, and the data were collected in the selected 
reaction monitoring (SRM). The MS/MS parameters were as follows: capillary voltage, 
3 kV; source temperature, 150 °C; cone gas flow rate, 80 L/h and desolvation gas flow 
rate, 800 L/h; desolvation temperature, 400 °C. Nitrogen (>99% purity) and argon (99% 
purity) were used as the nebulizing and collision gases, respectively. The SRM 
transitions and the individual cone voltages and collision energies were optimized for 
each analyte by injection of each standard compound into a mixture of methanol/water 
(1:1, v/v) at a concentration of 10 mg/L. Two SRM transitions were studied to find the 
most abundant product ions, selecting the  
most sensitive transition for quantification and the second one for identification 
purposes. When standard phenolic compound were not available, the SRM parameters 
were selected by analysing the real sample in fullscan mode in MS and daughter-scan 
mode in tandem MS. Table S2 of Supplementary Material shows the tandem MS (MS/ 
MS) transitions for quantification and confirmation, as well as cone voltage and 
collision energy values optimized for each phenolic compound. Table S2 also shows the 
commercial standards used to quantify each phenolic compound. When standard 
compounds were not available, the phenolic compound was tentatively quantified with 
its aglycone or with a phenolic compound with similar chemical structure. 
 
2.6. Instrumental quality parameters 
 
The instrumental quality parameters of the developed method, such as linearity, 
calibration curve, reproducibility, accuracy, detection limits (LODs) and quantification 
limits (LOQs) as well as extraction recovery and matrix effect were determined with a 
serial dilution of blank biological sample (plasma, urine, faeces, tissues and intestinal 
contents) with the standard phenolic compounds. The determination and calculation of 
these quality parameters are reported in our previous study (Suárez et al., 2009). The 
precision of the methods and accuracy were determined at three concentration levels, 
but only one concentration level is shown. The calibration curves (based on peak 
abundance) were plotted using y = a + bx, where y is the peak abundance ratio 
(analyte/internal standard) and x is the concentration ratio (analyte/internal standard). 
The internal standard (IS) used was catechol. For the other tissues (stomach, caecum, 
intestine and faeces), the calibration curves were plotted without IS, since catechol 
could be a metabolite. 
 
 
2.7. Statistical analysis 
Differences between diet groups were evaluated using a one-way ANOVA, followed by 
the LSD post-hoc test. Differences were considered statistically significant at p < 0.05. 
All analyses were performed with the Statgraphics Centurion XVI software (Statpoint 
Technologies Inc., Warrenton, VA, USA). 
 
3. RESULTS AND DISCUSSION 
 
3.1. Validation of the analytical procedure 
 
Blank plasma, urine, faeces, intestinal contents and tissue samples with different 
phenolic concentration were analysed by sample pre-treatment and UPLC-MS/MS to 
determine the linearity, calibration curve, precision, accuracy, LOD and LOQ. The 
obtained results are shown in Table S3 of the Supplementary Material.  
The precision of the method for all the biological fluids and tissues was below 15%. 
The accuracy of the method for the different samples was between 95 and 105%. The 
extraction recovery (%R) and matrix effect (%ME) of the phenolic compounds in the 
different biological samples were higher than 75% and lower than 18%, respectively. 
Once the instrumental quality parameters of the developed methods were studied, these 
were applied for the determination of hydroxytyrosol, oleuropein and their generated 
metabolites in the different biological samples  
 
3.1. Phase I and II metabolism of HT, SEC and OLE in the gastrointestinal tract 
 
Table 1 shows the phase I and II phenolic metabolite concentrations (nmols/g digesta) 
detected in the GIT contents (stomach, small intestine and caecum) and faeces after the 
diet supplementation (21 days) with 5 mg/kg weight rat/day of HT, SEC and OLE. The 
corresponding proposed pathways for phase I and II metabolism of the three HT 
precursors are shown in Fig. 2.  
At the gastric level, the SEC group underwent a complete degradation of the main 
secoiridoid 3,4-DHPEA-EDA (Table 1), which was hydrolysed into HT and EA and 
further metabolized (Fig. 2). OLE underwent a similar process in the stomach but a 
remaining amount of the native form was detected, indicating that OLE molecule was 
more resistant to the gastric acidic hydrolysis than 3,4-DHPEA-EDA. Accordingly, 
previous studies have shown that OLE is stable in human gastric juice (Corona et al., 
2006; Vissers, Zock, Roodenburg, Leenen, & Katan, 2002) and 3,4-DHPEA-EDA has 
been shown to be more sensitive to temperature, pH and enzyme activity compared with 
the glycoside form of OLE (Briante et al., 2002). In stomach, both the administered HT 
and the resulting HT from the hydrolysis of OLE and SEC underwent direct sulphation 
(hydroxytyrosol sulphate, Sulf) or methylation (homovanillic alcohol, HVAlc) and a 
further oxidation process (homovanillic acid, HVAc) followed by sulphation (HVAc-
Sulf and HVAlc- Sulf) with a remaining amount of free HT and observing very similar 
 
metabolic profiles among the three HT precursors (Table 1 and Fig. 2). Very few 
studies have analysed the in vivo metabolic capacity of the gastric mucosa to conjugate 
phenolic compounds, however, the presence of SULT1C2 isoform have been described 
in the stomach tissue (Nimmagadda, Cherala, & Ghatta, 2006). In a previous study by 
Zhao, Egashira, and Sanada (2004) they found that ferulic acid did not undergo any 
metabolic change in rat stomachs. In contrast, our results indicated that HT can suffer 
phase II metabolism at the gastric level of digestion, sulphation being the main 
conjugation process.  
The detection of higher concentrations of phase I and II metabolites in the small 
intestine contents after the administration of the three precursors revealed an intense 
enzymatic activity in the intestinal epithelium with an efflux transport of the metabolites 
into the gut lumen, a phenomenon that has already been described for olive oil phenolic 
compounds (D’Angelo et al., 2001; Manna et al., 2000). It is worth noting that HVAc 
and its conjugated forms, HVAc-Sulf and HVAc-Glu, were the metabolites detected at 
the highest concentrations in the intestinal lumen in all groups including the control 
group (Table 1). HVAc is the major molecular species deriving from endogenous 
dopamine metabolism through the action of monoamine oxidase and catechol-O-
methyltransferase in the central nervous system, which indicates that HVAc and its 
conjugated forms detected in the present study might be mainly of endogenous origin 
(D’Angelo et al., 2001). During digestion in the small intestine, part of the native form 
of OLE remained unaltered without being deglycosylated, resisting the action of lactase 
phlorizin hydrolase (LPH), an enzyme found in the lumen of the brush border of the 
small intestine with β-glucosidase activity towards glycoside compounds such as 
flavonoids (Del Rio et al., 2013). Compared to HT and SEC groups, OLE also presented 
in the small intestine significantly higher concentrations of some phase II metabolites 
such as HVAc-Sulf and hydroxytyrosol acetate sulphate (HTAc-Sulf) (Table 2). These 
results could indicate that OLE could suffer less 
 
Table 1 – Phase I and II metabolites’ concentration (nmols/g digesta) in the stomach and intestinal 
(gut and caecum) contents and faeces obtained after the diet supplementation (21 days) with 5 mg/kg 
weight rat/day of hydroxytyrosol (HT), secoiridoids (SEC) and oleuropein (OLE). The results are 
expressed as the mean ± SEM. 
Phenolic compound Control HT SEC OLE 
Stomach content 
(nmols/g digesta) 
    
Hydroxytyrosol n.d. 12.0 ± 2.69b 8.75 ± 1.95b 3.64 ± 0.79a
Hydroxytyrosol sulphate 0.16 ± 0.13a 3.28 ± 1.17b 10.5 ± 10.2b 3.45 ± 1.47b
Homovanillic acid 1.67 ± 0.87a 9.13 ± 1.74bc 4.32 ± 1.95ab 12.2 ± 4.12c
Homovanillic acid sulphate n.d. 0.17 ± 0.14a 4.03 ± 2.66b 0.55 ± 0.25a
Homovanillic alcohol n.d. 0.45 ± 0.29a 4.74 ± 3.34b 0.75 ± 0.22a
Elenolic acid sulphate – – 6.99 ± 2.55b 4.02 ± 1.25a
Oleuropein – – n.d. 4.14 ± 2.31 
Small intestine (nmol/g 
digesta) 
 
 
Hydroxytyrosol sulphate 8.03 ± 1.53a 30.5 ± 5.75b 31.1 ± 12.6b 29.6 ± 6.22b
Hydroxytyrosol n.d. 1.44 ± 0.91a 2.99 ± 0.53b 2.77 ± 0.58b
Hydroxytyrosol acetate 28.7 ± 8.63a 27.0 ± 7.36a 32.1 ± 6.5a 56.3 ± 13.0b
Homovanillic acid sulphate 48.3 ± 17.6a 36.6 ± 11.3a 50.8 ± 12.1ab 76.8 ± 14.4b
Homovanillic alcohol 16.0 ± 5.19ab 14.8 ± 2.67a 27.4 ± 7.74bc 32.9 ± 7.17c
Oleuropein – – n.d. 6.95 ± 3.34 
Caecum content (nmols/g 
digesta) 
  
Hydroxytyrosol 0.36 ± 0.24a 6.02 ± 1.32b 0.04 ± 0.00a 5.57 ± 0.65b 
Hydroxytyrosol sulphate n.d. 0.52 ± 0.52a n.d. 3.12 ± 2.25b 
Elenolic acid sulphate – – 0.02 ± 0.01a 9.38 ± 4.59b 
Faeces (nmols/g)   
Hydroxytyrosol n.d. 6.20 ± 1.35c 0.35 ± 0.01a 3.12 ± 0.35b
Hydroxytyrosol sulphate n.d. 1.44 ± 0.78 0.01 ± 0.01 0.01 ± 0.01 
n.d.: not detected. 
a–c   Indicate the levels which contain a significant difference at the 95.0% confidence level 
compared with the others in the same row. 
degradation thanHT and SEC under alkaline intestinal conditions and therefore, it could 
have been more exposed to phase II metabolism. In faeces, the intact form of OLE was 
not detected, in contrast to a previous study in which OLE, HVAc, EA and OLE 
aglycone were detected in rat faeces collected over 24 h after an acute oral dose of OLE 
(Lin et al., 2013). This discrepancy could be explained by the differences in the 
administered dose, the dose administered in the present work being much lower (5 
mg/kg vs 100 mg/kg). The free form of HT was detected in both the caecum content 
and the faeces, mainly in HT and OLE groups. In our previous work, free HT was also 
detected in human faeces after a sustained intake of an olive oil enriched with its own 
phenolic compounds (Mosele et al., 2014). Therefore, the present results confirm that 
the free form of HT is able to reach the large intestine, which could appear as a result of 
the deconjugation of the phase II metabolites by the action of the microbial enzymes, 
including β-glucuronidase and sulphatase (Selma, Espin, & Tomas-Barberan, 2009; 
Valdés et al., 2015).  
 
3.2. Microbial metabolism of phenolics in the intestinal tract 
 
The results showed that the microbial metabolism of HT, OLE and SEC started in the 
small intestine and was intensified in the lower part of the gut (caecum), detecting 
metabolites derived from oxidation, dehydroxylation, decarboxylation (α-oxidation) and 
carboxylation reactions along the GIT (Table 2, Figs 3–5). The microbial content of the 
GIT changes along its length, starting with a low number of microbes in the stomach, 
and increasing in the jejunum and the ileum, which are colonized by aerobe or 
facultative anaerobes. The highest concentrations are reached in the large intestine where 
the main microorganisms are anaerobes (Tiihonen, Ouwehand, & Rautonen, 2010; Zhao 
et al., 2015), which is in accordance with the amount of catabolites detected in caecum in 
the present study. Therefore, differences observed in the colonic metabolites can be 
attributed to the diverse microbiota populations that cause differences in the metabolite 
complexity in different sections of the digestive tract (Ouwehand & Vesterlund, 2003). 
 
The results of this study demonstrated that each administered HT precursor underwent 
different catabolic transformations with more or less intensity depending on the 
molecular structure of the precursor. In the case of the free form of HT, we observed that 
the predominant microbial metabolic transformation was the oxidation, converting the 
primary alcohol into dihydroxyphenylacetic acid (diHPAAc), followed by rapid and 
subsequent dehydroxylation giving rise to hydroxyphenylacetic acid (HPAAc), which 
was the most abundant microbial metabolite after HT treatment (Table 2 and Fig. 3). 
HPAAc could be further carboxylated leading to the 
Fig. 2– Phase I and II metabolism pathways of HT, OLE and SEC. COMT: 
catechol-O-methyltransferase enzyme; SULF: sulphotransferase enzyme; 
UGT: glucuronosyl-transferase enzyme. 
 
formation of hydroxyphenylpropionic acid (HPPAc) (Fig. 3), being the second most 
abundant microbial metabolite after HT intake (Table 2). The microbial origin and 
formation of these metabolites were demonstrated in our previous in vitro fermentation 
study with free HT (Mosele et al., 2014). When SEC was administered to rats, the 
microbial metabolic profile in GIT contents was similar to the HT group, lower 
concentrations (Fig. 4). On the other hand, OLE was characterized to undergo the same 
transformations as described in HT and SEC but in less intensity, and in addition, it 
suffered other kinds of microbial transformations. So, apart from the loss of a hydroxyl 
group, di- and mono-phenylacetic acids were also decarboxylated (α-oxidation) into 
phenolic compounds with lower molecular weights, including protocatechuic acid 
(PCAc) and 
hydroxybenzoic acid (HBZAc) (Fig. 5). HBZAc was predominately transformed to its 
glycine conjugate termed hydroxyhippuric acid (HHiPAc), which could suffer a further 
 
dehydroxylation and generate hippuric acid (HiPAc), a microbial transformation 
previously reported (Beyoglu & Idle, 2012). Consequently, of the three groups, OLE 
showed the most diverse microbial transformations and led to the formation of 
fermentation products with lower molecular weight (Table 2). 
A significant higher concentration of diHPPAc was also observed after OLE compared 
to SEC and HT, which could be in great part due to the hydrolysis of OLE- aglycone 
into HTAc with a subsequent de-  
Table 2 – Concentration (nmols/g digesta) of the microbial phenolic metabolites detected in the 
intestinal (gut and caecum) contents, and faeces obtained after the diet supplementation (21 
days) with 5 mg/kg weight rat/day of hydroxytyrosol (HT), secoiridoids (SEC) and oleuropein 
(OLE). The results are expressed as mean ± SEM.
Phenolic metabolite Control HTT  SEC  OLE
Small intestine (nmols/g 
digesta) 
      
Hydroxyphenylpropionic acid 9.29 ± 1.22a 16.7 ± 1.22b 11.8 ± 1.60a  12.1 ± 1.33a
Hydroxyphenylpropionic acid 2.57 ± 1.74a 16.2 ± 6.15b 15.4 ± 6.18b  38.8 ± 9.27c
Hydroxyphenylacetic acid  
sulphate 
13.6 ± 3.83a 12.4 ± 6.10a  30.4 ± 9.06ab  40.9 ± 6.22b 
Catechol n.d. 2.73 ± 0.63b 0.68 ± 0.21a  4.32 ± 0.18c
Hippuric acid 161 ± 49.9a 186 ± 47.5a 223 ± 50.1a  367 ± 72.5b
Caecum content 
(nmols/g digesta) 
      
Dihydroxyphenylpropionic 89.0 ± 60.3a 195 ± 77.8ab 147 ± 25.9ab  403 ± 226b
Hydroxyphenylpropionic acid n.d. 592 ± 143b 316 ± 70.4a  252.09 ± 
Dihydroxyphenylacetic acid 16.5 ± 5.26a 50.4 ± 13.9b 25.1 ± 7.40a  31.9 ± 12.5ab
Hydroxyphenylacetic acid* 65.1 ± 31.8a 707 ± 31.1c 493 ± 37.9b  309 ± 99.08b
Hydroxyphenylacetic acid 1.47 ± 0.97a n.d. 6.14 ± 5.16a  34.9 ± 19.0b
Phenylacetic acid n.d. 26.52 ± 24.5 ± 2.18a  n
Catechol 0.36 ± 0.28a 1.62 ± 0.23b  1.13 ± 0.17b  1.67 ± 0.22b 
Faeces (nmols/g)       
Hydroxybenzoic acid 0.63 ± 0.32a 0.46 ± 0.21a 2.97 ± 1.59b  5.82 ± 2.12c
Hippuric acid 8.67 ± 0.44a 6.65 ± 6.32a 16.1 ± 4.34a  48.84 ± 
Phenylacetic acid 52.7 ± 13.0a 70.2 ± 9.53ab 268 ± 43.1b  293 ± 50.0b
n.d.: not detected. 
*  ∑ p- and o-hydroxyphenylacetic acid. 
a–c   Indicate the levels which contain a significant difference at the 95.0% 
confidence level compared with the others in the same row. 
esterification, oxidation and carboxylation (Fig. 5). This metabolic pathway was 
described in our previous work, in which OLE was fermented in vitro with human 
faeces (Mosele et al., 2014). 
Once in the portal bloodstream, microbial metabolites can rapidly reach the liver, where 
they can be subjected to further phase II metabolism, and enterohepatic recirculation 
may result in some recycling back to the small intestine through bile excretion. This 
could explain the detection of metabolites such as HPPAc-Sulf, HPAAc- Sulf and 
HPAAc-Glu in the small intestine and caecum contents, mainly after the OLE 
administration.  
The biological activities of the products of microbial fermentation of olive phenols have 
 
not yet been systematically tested. However, a few reports have demonstrated that 
products of the colonic degradation of flavonoids, such as phenylacetic and 
phenylpropionic acids and their derivates, exhibit anti-inflammatory effects (Larrosa et 
al., 2009). 
 
Fig. 3 – Proposed catabolism pathways of HT by the gut microbiota 
derived from the analysis of small intestine (SI) and caecum (C) contents 
and faeces (F). Compounds that were detected after HT treatment are 
highlighted in grey colour. DOH: dihydroxylation; SULF: 
sulphotransferase enzyme. *Phase II metabolism (sulphation) in liver of 
some compounds that were detected in the GIT after enterohepatic 
recirculation. 
 
as well as antioxidant powers (Jaganath, Mullen, Lean, Edwards, & Crozier, 2009). It 
has also been pointed out that the local concentration of intact polyphenols and its 
metabolites that reach the intestine may have a significant redox effect (Scalbert et al., 
2000). This might be the case of olive phenols, which in the present study, no matter the 
precursor (HT, SEC or OLE), have all been demonstrated to undergo extensive 
transforma tions in the GIT, resulting in the release of a large number of putative 
bioactive compounds, varying depending on the precursor compound. Metabolites could 
also be reabsorbed and exert their action in the colon as well as in other target tissues 
after absorption. Wang, Williams, Ferruzzi, and D’Arcy (2013) demonstrated the 
transference of some phenolic fermentation products across the Caco-2 cell monolayer. 
The results from the microbial metabolism in the present study are in close agreement 
with our previous in vitro fermentation experiments performed with human faecal 
inoculums (Mosele et al., 2014), which 
 b
 
 
 
Fig
. 4 – 
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-EDA (main compound in the SEC extract) by the gut microbiota derived from the 
analysis of small intestine (SI), caecum contents (C) and faeces (F). DOH: 
dihydroxylation; SULF: sulphotransferase enzyme. *Phase II metabolism (sulphation) 
in liver of some compounds that were detected in the GIT after enterohepatic 
recirculation. 
 
 suggests that the rat model can be a good approach to performing a human 
approximation of the digestion and microbial metabolism of olive phenolic compounds. 
In fact, rodent animals are similar to humans at both the host geneticand the taxonomic 
levels of the microbiota, particularly at the phylum level. However, important 
differences may be appreciated at the lower taxonomic level (Kostic, Howitt, & Garrett, 
2013). Moreover, it should remain clear that the amount and identity of the catabolites 
detected may significantly vary from individual to individual, as observed in the high 
deviation values in some determinations.  
 
3.3. Plasma, urine excretion and tissue deposition 
 
Table 3 shows the concentration of the phase I and II phenolic metabolites in plasma and 
urine after the sustained intake of free HT and its conjugated precursors OLE and SEC. 
Phenolic compound Control HT SEC OLE 
Plasma (µM)   
Hydroxytyrosol sulphate n.d. 0.37 ± 0.03 0.36 ± 0.08 0.32 ± 0.07 
Homovanillic alcohol n.q 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.00 
Elenolic acid 
l id
n.q – 0.09 ± 0.03
a
 0.22 ± 0.04
b
 
Urine (µmol)     
Hydroxytyrosol n.d. 0.03 ± 0.02a 5.38 ± 0.48b 4.01 ± 2.06b 
Homovanillic acid n.d. 4.26 ± 0.73a 9.11 ± 0.54a 169 ± 39.2b 
Hydroxytyrosol sulphate n.d. 57.4 ± 13.54a 72.6 ± 10.5a 169 ± 28.6b 
Homovanillic acid n.d. 85.6 ± 5.26a 92.6 ± 5.50a 557 ± 89.9b 
Elenolic acid sulphate n.d. – 4.75 ± 0.90 6.95 ± 1.28 
Hydroxytyrosol-4-O- n.d. 1.56 ± 0.25b 0.46 ± 0.06a 1.80 ± 0.38b 
Homovanillic acid n.d. n.d. 4.17 ± 0.30 a 28.4 ± 5.35b 
Elenolic acid 0.38 ± 0.09a – 18.5 ± 3.13b 61.0 ± 9.14c 
Methyloleuropein n.d. – n.d. 1.63 ± 0.29 
Oleuropein n.d. – n.d. 2.13 ± 0.66 
Oleuropein aglycone n.d. – 0.13 ± 0.02a 1.49 ± 0.22b 
Oleuropein aglycone n.d. – n.d. 2.03 ± 0.13 
n.d.: not detected; n.q.: not quantified. 
a–c   Indicate the levels which contain a significant difference at the 95.0% 
confidence level compared with the others in the same row. 
The results in plasma revealed that very low concentrations of metabolites were detected 
(nanomolar range), probably due to the low daily dose administered in this study and the 
distribution of the dose over the day. No differences were observed between the three groups, 
except for EA-Glu, which was only detected in the plasma of OLE group. A previous study 
performed in our lab (Serra et al., 2012) showed that after an acute intake by rats of an olive 
phenolic extract rich in SEC, the sulphate conjugates of HT and the native forms of OLE 
 and HT were detected in plasma at higher concentrations (between 21 and 89 µM) 
probably due to the higher administered dose (180 mg SEC/kg rat weight). We observed 
a similar metabolic fate after an acute intake of HT at different doses (1, 10, and 100 
mg/kg rat weight), sulphation again being the most relevant conjugation pathway at the 
three administered doses (López de Las Hazas et al., 2015). The present study provides 
new data after a sustained intake of olive phenolic compounds, showing that when 
nutritionally relevant doses are administered in rats, a lower variety of metabolites is 
detected in the plasma (only HT-Sulf and HVAlc-Sulf) and at lower concentrations. In 
contrast to the plasma, 
urine recovery of metabolites showed significant differences among the three HT 
precursors administered. Urine excretion of phase I and II metabolites was significantly 
higher when OLE was admi nistered in comparison with HT or SEC (Table 3). In some 
cases, such as for HVAc, the metabolite was 50-fold higher in the OLE than the other 
groups. Thus, it can be concluded from the urine excretion results that, among the three 
groups, the bioavailability of HT was more effective 
 
 
Fig. 5- Proposed catabolism pathway of OLE by the gut microbiota derived from the 
analysis of small intestine (SI), caecum contents (C) and faeces (F). DOH: 
dihydroxylation; SULF: sulphotransferase enzyme; UGT: glucuronosyl-transferase 
enzyme. *Phase II metabolism (sulphation and glucuronidation) in liver of some 
compounds that were detected in the GIT after enterohepatic recirculation. 
 
 
after the diet supplementation with OLE. In fact, it has been established that 24 h- urine 
offers advantages over plasma measurements, mostly because they allow an accurate 
evaluation of the total polyphenols absorbed due to the very short plasma half-lives of 
the polyphenols (Medina - Remón, Tresserra - Rimbau, Arranz, Estruch, & Lamuela-
Raventos, 2012). Regarding the colonic phenolic metabo-lites detected in the intestinal 
contents and faeces, a very low concentration of these metabolites was detected in the 
urine samples, and no significant differences were observed among the three groups or 
compared to the control (data not shown). These results could indicate rather that urine 
sampling of up to 24 h could be required to detect these HT microbial metabolites, or 
that they were not reabsorbed at colonic level. 
So, results from plasma and urine showed that depending on the molecular structure of 
the HT precursors, the bioavailability could differ. In accordance, previous studies 
showed that the bioavailability of flavonoids also varied depending on their chemical 
structure. Results obtained from plasma and urinary levels of flavanol stereoisomers 
after their oral intake, showed that the ranking for the oral absorbability of flavanols 
was as follows: (−)-epicatechin > (+)-epicatechin = (+)-catechin > (−)-catechin, (−)-
epicatechin (Ottaviani et al., 2011). Moreover, the sugar moiety of flavonoids has been 
suggested as an important determinant in their absorption in humans. Typically, 
absorption of flavonoid glycosides is associated with the release of the aglycone as a 
result of the action of LPH enzyme with β-glucosidase activity. However, a great part of 
the polyphenol conjugates with sugar moieties are resistant to the action of LPH 
enzymes and pass to the colon, where the colonic microbiota cleave conjugating 
moieties (Del Rio et al., 2013). This might be the case of the glycoside molecule of 
OLE, which could have been in part hydrolysed by LPH enzymes leading to HT in the 
upper part of the GIT, and another important amount of OLE could have passed to the 
colon. 
Regarding the tissue distribution, in contrast to our previous study (Serra et al., 2012), 
in which a similar olive phenolic extract was administered to rats, in the present study, 
very few HT metabolites were detected in liver and kidney and at very low 
concentrations with no significant differences among the HT, SEC and OLE groups 
(Table S4 of Supplementary Material). This fact could be due to the low daily dose 
administered (5 mg/kg rat weight/day) and the tissue perfusion with isotonic solution 
performed to remove the remaining blood irrigating tissues after the sacrifice of the rats. 
Accordinly with our previous study, HT-Sulf appeared again as the most deposited 
metabolite in both liver and kidney tissues. 
 
4. CONCLUSIONS 
 
The results from the present study show that, of the three HT precursors, the maximum 
efficiency in the bioavailability of HT and its metabolites was observed after diet 
supplementation with OLE. This could be due to the higher stability of OLE under 
digestion conditions observed along the GIT, which could have led to a major exposure 
of OLE to phase II metabolism. The higher bioavailability of HT through OLE was 
 
mainly reflected in the urine excretion of phase I and II metabolites. Moreover, OLE as 
a glycoside molecule could have resisted in part the action of the β-glucosidase 
enzymes in the small intestine and passed unaltered to the colon with the resultant 
higher production of microbial fermentation catabolites with potential biological 
activity. The findings from this study revealed that the absorption and biotransformation 
of HT depends mainly on its precursor. Further studies are needed to find a possible 
correlation with biological efficacy, but in terms of bioavailability and microbial 
fermentation, the results indicate that OLE is the most suitable HT derivate for use in 
food or nutraceutical formulations. 
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SUPPLEMENTARY MATERIAL 
 
Table 1 of Supplementary Material. Phenolic composition of the 
secoiridoid extract (SEC) and nutritional composition of the standard 
fed pellets. 
 
Secoiridoid extract 
Compound Concentration (mg/kg extract) 
HT 4176.82 ± 185.40 
p-HPEA-EDA 936.37 ± 60.66 
3,4-DHPEA-EDA 40995.97 ± 1085.46 
p-HPEA-EA 378.82 ± 21.63 
3,4- DHPEA-EA 1628.98 ± 274.01 
OLE 480.00 ± 70.33 
Standard fed pellets 
Ingredients: Wheat, corn, corn gluten, calcium carbonate, 
soybean oil, dicalcium phosphate, iodized salt, aminoacids 
mix, minerals and vitamins. 
Component % of diet 
Proteins 14.3 % 
Fat 4 % 
Carbohydrates 48 % 
Fibers (∑ crude & neutral) 21 % 
∑ minerals 2.7 % 
∑ aminoacids 10.5 % 
∑ vitamins (A, D, E, K, B1, B2, Niacin, B6, Pantothenic 
Acid, B12, Biotin, Folate, Choline) 
 
Values of extracts are means ± SD (n= 4). HT: 
Hydroxytyrosol; p-HPEA- EDA: Dialdehydic form of 
elenolic acid linked to tyrosol; 3,4-DHPEA-EDA: 
Decarboxymethyl elenolic acid linked to hydroxytyrosol; p-
HPEA-EA: Aldehydic form of elenolic acid linked to tyrosol; 
3, 4- DHPEA-EA: Isomer of oleuropein aglycone. OLE: 
oleuropein. 
  
  
Table 2 of Supplementary Material. SRM conditions for the analysis of phenolic metabolites by UPLC-MS/MS. 
Quantification (SRM1) Identification (SRM2) 
Standard in which  
has been quantified 
Phenolic compound 
SRM 
Cone 
voltage 
(V) 
Collision 
energy 
(eV) 
SRM Cone voltage (V)
Collision 
energy 
(eV) 
 
Hydroxytyrosol 153  123 35 10 153  95 35 25 
Hydroxytyrosol 
Hydroxytyrosol sulfate 233  153 40 15 233  123 40 25 
Hydroxytyrosol-3-O-sulfate 
Hydroxytyrosol disulfate 313  233 40 10 313  153 40 30 
Hydroxytyrosol-3-O-sulfate 
Hydroxytyrosol-3-O-
glucuronide 329  153 40 20 
329  
123 40 25 
Hydroxytyrosol 
Hydroxytyrosol-4-O-
glucuronide 329  153 40 20 
329  
123 40 25 
Hydroxytyrosol 
Homovanillic alcohol 167  152 35 15 167  122 35 25 
Hydroxytyrosol 
Homovanillic alcohol 
sulphate 247  167 40 15 
247  
152 40 25 
Hydroxytyrosol 
Homovanillic alcohol 
glucuronide 343  167 40 20 
343  
152 40 35 
Hydroxytyrosol 
Homovanillic acid 181  137 25 10 181  122 25 15 
Hydroxytyrosol 
Homovanillic acid sulphate 261  181 40 15 261  137 40 25 
Hydroxytyrosol 
Homovanillic acid 
glucuronide 357  181 40 20 
357  
137 40 30 
Hydroxytyrosol 
Hydroxytyrosol acetate 
sulphate 275  153 35 15 
275  
123 35 30 
Hydroxytyrosol 
Elenolic acid 241  139 30 15 241  127 30 20 
Hydroxytyrosol 
Elenolic acid sulphate 321  241 40 15 321  40 20 Oleuropein 
  
 
139 
Elenolic acid glucuronide 417  241 40 15 417  139 40 20 
Oleuropein 
Oleuropein  539  377 35 15 539  275 35 20 
Oleuropein 
Oleuropein glucuronide 715  539 55 15 715  377 55 25 
Oleuropein 
Oleuropein aglycone sulfate 457  377 40 15 457  275 40 20 
Oleuropein 
Oleuropein aglycone 
glucuronide 553  377 40 15 
553  
377 40 20 
Oleuropein 
Methyl oleuropein aglycone 
sulfate 471  391 40 15 
391  
275 40 20 
Oleuropein 
Oleuropein aglycone 
derivate 1 555  523 40 15 
555  
275 40 25 
Oleuropein 
Oleuropein aglycone 
derivate 2 571  539 40 15 
571  
377 40 25 
Oleuropein 
Catechol  108.9  
90.9 40 15 - - - 
Catechol  
Phenylacetic acid 135  91 20 5 - - - HPA 
Hydroxyphenylacetic acid 151  107 20 10 - - - HPA 
Hydroxyphenylacetic acid 
sulphate 231  151 20 20 
231  
107 20 25 HPA  
Hydroxyphenylacetic acid 
glucuronide 327  151 20 15 
327  
107 20 25 HPA 
Dihydroxyphenylacetic acid 167  123 20 10 - - - DHPA  
Hydroxybenzoic acid 137  93 30 15 - - - HPA 
Protocatechuic acid 153  109 45 15 - - - Hydroxytyrosol  
Hydroxyphenylpropionic 
acid 165  121 20 10 - - - HPP 
Hydroxyphenylpropionic 
acid sulphate 245  165 35 15 
245  
121 35 20 HPP 
  
 
Dihydroxyphenylpropionic 
acid 181  137 20 15 - - - HPP 
Hippuric acid 178  134 40 10 - - - Hippuric acid 
Hydroxyhippuric acid 194  100 40 10 - - - Hippuric acid 
HPA: p-Hydroxyphenylacetic acid; HPP: 3-(4-Hydroxyphenyl)propionic; DHPA: 3,4-Dihydroxyphenylacetic 
Table 3 of Supplementary Material. Linearity, calibration curves, reproducibility, accuracy, LOD and LOQs for the analysis of the 
commercial studied phenolic compounds by UPLC-MS/MS in spiked biological samples. 
 
a) Plasma samples * 
Phenolic compound Linearity (µM) Calibration curve RSD (%) (n=3) (0.5 µM) 
Accuracy (n=3) 
(0.5 µM) LOD (µM) LOQ (µM) 
Hydroxytyrosol 0.03-2.77 y = 9.425 x + 0.013 11.2 98 0.002 0.005 
Hydroxytyrosol-3-O-
sulfate 
0.03-277 y = 3.486 x + 0.024 9.8 102 0.005 0.015 
 
b) Urine samples * 
Phenolic compound Linearity (µM) Calibration curve 
RSD (%) 
(n=3) 
(25 µM) 
Accuracy (n=3) 
(25 µM) LOD (µM) LOQ (µM) 
Hydroxytyrosol 0.03-94.98 y = 5.412 x + 0.042 14.2 103 0.01 0.03 
Oleuropein  0.07-78.67 y = 63.158 x – 0.107 13.4 99 0.02 0.07 
 
c) Liver samples * 
Phenolic compound Linearity (µM) Calibration curve RSD (%) (n=3) (2.5 µM) 
Accuracy (n=3) 
(2.5 µM) LOD (µM) LOQ (µM) 
Hydroxytyrosol 0.009-179 y = 266.2 x + 0.019 9.8 100 0.003 0.009 
Oleuropein  0.05-54.03 y = 108.85 x – 0.085 7.5 97 0.02 0.05 
 
d) Kidney samples * 
Phenolic compound Linearity (µM) Calibration curve RSD (%) (n=3) Accuracy (n=3) LOD (µM) LOQ (µM) 
  
 
(2.5 µM) (2.5 µM) 
Hydroxytyrosol 0.60-72.88 y = 7.811 x – 0.019 10.2 97 0.20 0.60 
Oleuropein  0.08-21.95 y = 25.934 x – 0.019 9.5 96 0.03 0.08 
 
 
e) Stomach content samples * 
Phenolic compound Linearity (µM) Calibration curve 
RSD (%) (n=3) 
(5 µM) 
Accuracy (n=3) 
(5 µM) LOD (µM) LOQ (µM) 
Hydroxytyrosol  0.03-636.36 y = 59.92 x + 65.54 7.9 96 0.01 0.03 
Oleuropein  0.40-191.67 y = 305.74 x – 389.78 8.6 102 0.15 0.40 
 
f) Small intestine content samples  
Phenolic compound Linearity (µM) Calibration curve 
RSD (%) (n=3) 
(10 µM) 
Accuracy 
(n=3) 
(10 µM) 
LOD (µM) LOQ (µM) 
Hydroxytyrosol  0.3-636.36 y = 108.02 x – 99.243 10.1 104 0.15 0.3 
Oleuropein  0.19-191.67 y = 133.37 x + 529.84 12.6 103 0.03 0.19 
p-Hydroxyphenylacetic 
acid 
0.01-112.83 y = 520.91 x + 469.32 10.1 99 0.003 0.01 
3,4-Dihydroxyphenylacetic 
acid 
0.55-544.64 y = 63.319 x – 569.53 8.6 102 0.18 0.55 
3-(4-Hydroxyphenyl)propionic
acid 
0.84-1084.34 y = 24.08 x + 159.63 9.9 97 0.25 0.84 
Hippuric acid 5.44-543.58 y = 80.624 x – 1640.4 12.8 95 2.44 5.44 
Catechol  0.3-745.75 y = 97.53 x – 124.56 10.5 105 0.15 0.3 
 
g) Caecum content samples  
Phenolic compound Linearity (µM) Calibration curve 
RSD (%) 
(n=3) 
Accuracy 
(n=3) LOD (µM) LOQ (µM) 
  
 
(5 µM) (5 µM) 
Hydroxytyrosol  0.004-636.36 y = 110.12 x – 98.147 12.4 102 0.001 0.004 
Oleuropein  0.004-592.67 y = 145.48x + 624.75 13.4 95 0.001 0.004 
p-Hydroxyphenylacetic acid 0.002-728.3 y = 518.22 x + 396.24 12.4 96 0.001 0.003 
3,4-Dihydroxyphenylacetic acid 0.45-544.64 y = 62.124 x – 475.04 11.5 99 0.15 0.45 
3-(4-Hydroxyphenyl)propionic 
acid 
0.84-1084.38 y = 20.084 x + 152.04 11.6 105 0.28 0.84 
Catechol  0.75-745.75 y = 102.64 x – 113.29 12.2 102 0.001 0.004 
 
 
h) Faeces  
Phenolic compound Linearity (µM) Calibration curve RSD (%) (n=3) (50 µM) 
Accuracy (n=3) 
(5 µM) 
LOD 
(µM) 
LOQ 
(µM) 
Hydroxytyrosol  0.01-636.36 y = 96.116 x – 60.08 12.4 97 0.003 0.01 
Hydroxytyrosol-3-O-sulfate 0.004-428.21 y = 450.49x + 142.58 11.9 99 0.001 0.004 
p-Hydroxyphenylacetic acid 0.004-567.70 y = 559.73 x + 1009.6 12.7 101 0.001 0.004 
Hippuric acid 0.54-543.58 y = 52.505 x – 120.03 13.0 103 0.2 0.54 
Catechol  0.75-745.75 y = 103.57 x + 139.85 12.2 102 0.001 0.004 
* Calibration curves (based on peak abundance) were plotted using y=a+bx, where y is the peak abundance ratio (analyte/IS) and 
x is the concentration ratio (analyte/IS). This was applied when catechol (IS) was not detected in samples.  
 Table 4 of Supplementary Material. Concentration of the metabolites detected in 
metabolic tissues (liver and kidney) obtained after the diet supplementation (21 days) 
with 5 mg/kg weight rat/day of hydroxytyrosol (HT), secoiridoids (SEC) and oleuropein 
(OLE). The results are expressed as the mean ± SEM. 
 
OLEPhenolic compound Control HT SEC 
Liver (nmol/g tissue)     
Hydroxytyrosol sulfate 0.03 ± 0.00a 2.74 ± 0.40b 3.23 ± 0.30b 2.05 ± 0.25b 
Homovanillic alcohol 
sulfate n.d. 0.34 ± 0.10
a 0.60 ± 0.07a 0.25 ± 0.02b 
Homovanillic acid 
glucuronide 0.01 ± 0.00
a 8.65 ± 0.86d 2.70 ± 0.07b 3.30 ± 0.06c 
Elenolic acid sulfate n.d. - 0.77 ± 0.49 0.55 ± 0.21 
Elenolic acid glucuronide n.d. - 0.35 ± 0.02 0.38 ± 0.06 
Methyloleuropein aglycone 
sulfate n.d. - 0.12 ± 0.01 0.12 ± 0.02 
Oleuropein n.d. - 0.19 ± 0.02 0.22 ± 0.05 
Kidney (nmol/g tissue)     
Hydroxytyrosol sulfate 1.82 ± 0.18a 8.69 ± 0.32b 6.65 ± 0.70b 5.62 ± 0.95b 
Homovanillic alcohol 
sulfate 
0.72 ± 0.12a 2.12 ± 0.22b 1.86 ± 0.19b 1.79 ± 0.28 
b 
Homovanillic acid 
glucuronide 
1.78 ± 0.08c 0.79 ± 0.05a 1.41 ± 0.11b 1.02 ± 0.11a 
Elenolic acid sulfate 0.16 ± 0.03 - 0.16 ± 0.06 0.11 ± 0.03 
 
Elenolic acid glucuronide 0.13 ± 0.04a - 0.55 ± 0.02b 0.20 ± 0.02a 
 
 
 
